menu
menu
Immuno-oncology
Each microlearning activity offers 0.5 CME/CMLE credit.
This course addresses the role of biomarker testing in resectable NSCLC, including PD-L1, EGFR, and ALK. You will also learn about the evaluation of posttreatment lung cancer resection specimens.
In this course, you will learn about the complexity of advanced NSCLC, including making accurate diagnosis on small samples, identifying actionable mutations, and determining PD-L1 expression levels.
In this course, you will learn about biomarkers for the diagnosis, prognosis, and prediction of therapeutic response in patients with advanced melanoma.
This course addresses measurement and scoring of pathologic response in resectable melanoma, best practices for specimen collection and handling, and immunotherapy-related pathologic response scoring systems to assess pathologic response.
This course will provide you with an increased understanding of health disparities impacting the ability of Black persons and other persons of color with cancer to access I-O therapies.
This course is designed to help you learn how PD-L1 testing and interpretation is performed using CPS.
In this course, you will learn key considerations when establishing a PD-L1 LDT and what is involved with validation and scoring different types of cancers.
This course will help you learn how PD-L1 testing and interpretation is performed in patients with advanced triple negative breast cancer (TNBC), including key considerations when assessing pathological complete response (pCR) following neoadjuvant therapy.
This course will provide you with an increased understanding of PD-L1 testing considerations.